Analyzing Foamix Pharmaceuticals (NASDAQ:FOMX) & Sundial Growers (NASDAQ:SNDL)

Foamix Pharmaceuticals (NASDAQ:FOMX) and Sundial Growers (NASDAQ:SNDL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, institutional ownership, profitability and earnings.

Earnings & Valuation

This table compares Foamix Pharmaceuticals and Sundial Growers’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Foamix Pharmaceuticals $3.60 million 61.34 -$74.16 million ($1.70) -2.13
Sundial Growers N/A N/A N/A N/A N/A

Sundial Growers has lower revenue, but higher earnings than Foamix Pharmaceuticals.

Profitability

This table compares Foamix Pharmaceuticals and Sundial Growers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Foamix Pharmaceuticals -2,115.11% -75.99% -66.29%
Sundial Growers N/A N/A N/A

Analyst Ratings

This is a breakdown of current recommendations for Foamix Pharmaceuticals and Sundial Growers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Foamix Pharmaceuticals 0 0 5 0 3.00
Sundial Growers 0 1 2 0 2.67

Foamix Pharmaceuticals presently has a consensus target price of $15.60, indicating a potential upside of 330.94%. Sundial Growers has a consensus target price of $14.33, indicating a potential upside of 102.73%. Given Foamix Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Foamix Pharmaceuticals is more favorable than Sundial Growers.

Institutional and Insider Ownership

47.2% of Foamix Pharmaceuticals shares are held by institutional investors. 3.0% of Foamix Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Foamix Pharmaceuticals beats Sundial Growers on 6 of the 9 factors compared between the two stocks.

About Foamix Pharmaceuticals

Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.

About Sundial Growers

Sundial Growers, Inc. produces, distributes, and sells cannabis. It intends to target the premium segment of the adult-use cannabis market. The company was founded by Stanley J. Swiatek and is headquartered in Calgary, Canada.

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit